CD8+ T-cells are the key lymphocytes for killing tumor cells, and it has been proven that their presence is necessary to achieve a response to a treatment with anti-PD-1 (programmed cell death 1) antibodies (29). This evidence concerns the gene PDCD1 and neoplasm.